Boston Scientific 8-K (2.02, 9.01): reported results of operations

Boston Scientific reported third-quarter 2026 sales of $5.138 billion, up 1.5%, GAAP EPS of $0.40 versus $0.51 a year earlier, and adjusted EPS of $0.73 versus $0.75, alongside clinical, regulatory and strategic collaboration updates.